Topic: obesity treatments
An enzyme that works on leptin receptors and a receptor protein called MC3R could be anti-obesity drug targets.
The round equips Gelesis to get its manufacturing and commercial arms ready for launch should regulators look favorably on its mixed late-phase data.
Scientists at Yale believe they’ve found an immune connection to the inability to burn belly fat—and a possible solution.
More than half of subjects who took the hydrogel particles lost weight, encouraging Gelesis to file for approval despite missing another endpoint.
The deal gives Boehringer access to Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
Allurion Technologies has raised $27 million in series C funding for its swallowable, procedureless, weight-loss balloon.
Scientists at Beth Israel Deaconess Medical Center are discovering why the process of feeling too full to eat any more goes awry in some people.
Less than a year ago, Zafgen was poleaxed by the failure of its lead weight-loss drug beloranib, shedding staff as its share price tumbled. Now, the Boston biotech is back with the first data on a follow-up it hopes will put it back on track.
Scientists at Cold Spring Harbor Laboratory in New York have created the first model of genetic obesity in fruit flies.